FPR2アゴニズムは,ELOVL6経由でネオインティマル・ハイパープラジアを緩和することによって,レステノスを緩和する
Qian Zhang1, Yuqin Zha1, Xiaoting Wang1
1State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
まとめ
形状ペプチド受容体2 (FPR2) の活性化により,血管の滑らかな筋肉細胞の分化が維持され,レステノシスが防止されます. FPR2/ELOVL6経路を標的にすることは,下肢動脈疾患の新たな治療戦略を提供します.
科学分野:
- 血管生物学
- 免疫学
- 薬理学について
背景:
- 下肢動脈疾患における血管内干渉後のレステノシスは,主要な臨床的課題です.
- フォルミルペプチド受容体2 (FPR2) は血管の炎症と再構成に作用する.
- 回復症の患者では,FPR2発現の低下が観察されています.
研究 の 目的:
- ネオインティマル・ハイパープラジアにおける FPR2の役割を調査する.
- FPR2アゴニストのBMS-986235の治療の可能性を評価する.
主な方法:
- 人間の動脈組織におけるFPR2発現の分析
- FPR2ノックアウトマウスモデルにおけるネオインティマルの増殖の評価
- マウスモデルにおけるBMS-986235による薬理学的介入
- トランスクリプトミックの分析で 下流の標的を特定する
主要な成果:
- FPR2のノックアウトマウスは 悪化したネオインティマル・ハイパープラジアを示した.
- BMS-986235の治療は,ネオインティマル・ハイパープラジアの進行を有意に減少させた.
- FPR2の活性化により,血管滑らかな筋肉細胞 (VSMC) の分化が維持され,M2マクロファージの蓄積が制限された.
- ELOVL脂肪酸エルンガゼ6 (ELOVL6) は,BMS-986235によってダウンストリーム対象として特定されました.
結論:
- FPR2の活性化により,FPR2/ELOVL6軸経由でVSMCの分化が維持されることで,レステノスが軽減されます.
- BMS-986235は,レステノスを予防する治療的可能性を示しています.
- FPR2は下肢動脈疾患に対する有望な治療標的です.
関連する概念動画
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
250
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
250
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
642
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
642
01:12GPCR Desensitization
6.4K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.4K
01:31Transducer Mechanism: Nuclear Receptors
1.6K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505